BridgeMD
New treatment option for Pancreatic Cancer
Official title Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
ClinicalTrials.gov ID: NCT05298722
What this study is testing
- What it's testing
- In this prospective study, new diagnostic tools will be explored for patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (BR or LAPDA) who undergo neoadjuvant chemotherapy with FOLFIRINOX. The diagnostic work-up and therapy for the study population will not differ from the gold standard during the study; only additional diagnostic tools will be implemented, and their value will be analyzed post hoc.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Male or female patients, aged 18 years and above
- Diagnosis of BR or LA PDAC according to NCCN guidelines (version 1.2020)
- Histologic diagnosis of PDAC
- No medical or anesthetic contra-indication for surgery
- Able to understand nature of the study procedures
You likely can't join if
- Age \< 18 years
- Distant metastases
- Histologic diagnosis of cholangiocarcinoma, duodenal carcinoma or neuroendocrine tumor
- Known hypersensitivity for MRI contrast
- Pacemaker or prosthesis with incompatibility for MRI
- Claustrophobia
See the full eligibility criteria
- Male or female patients, aged 18 years and above
- Diagnosis of BR or LA PDAC according to NCCN guidelines (version 1.2020)
- Histologic diagnosis of PDAC
- No medical or anesthetic contra-indication for surgery
- Able to understand nature of the study procedures
- Willing to participate and give written informed consent
- Age \< 18 years
- Distant metastases
- Histologic diagnosis of cholangiocarcinoma, duodenal carcinoma or neuroendocrine tumor
- Known hypersensitivity for MRI contrast
- Pacemaker or prosthesis with incompatibility for MRI
- Claustrophobia
- Pregnancy or breastfeeding
- Not able to understand nature of the study procedure
- Performance status ECOG score: \>2
The study team makes the final eligibility decision.
Where it's taking place
- Ghent, East Flanders, Belgium
- Dendermonde, Belgium
- Eeklo, Belgium
- Ghent, Belgium
- Oudenaarde, Belgium
- Sint-Niklaas, Belgium
- Terneuzen, Zeeland, Netherlands
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ghent, East Flanders, Belgium; Dendermonde, Belgium; Eeklo, Belgium; Ghent, Belgium; Oudenaarde, Belgium; Sint-Niklaas, Belgium and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.